Homemarket News

SAT dismisses Top Class Capital appeals against Sebi orders in insider trading case

SAT dismisses Top Class Capital appeals against Sebi orders in insider trading case

SAT dismisses Top Class Capital appeals against Sebi orders in insider trading case
Profile image

By PTI Mar 9, 2022 9:52 PM IST (Updated)

The appeals were filed against two orders passed by Sebi, whereby it had imposed a penalty of Rs 7.5 crore on Top Class Capital in September 2019 and through another order in August 2020, the regulator restrained the entity from the securities market for one year and for three years in dealing with the shares of Aurobindo Pharma Ltd.

The Securities Appellate Tribunal (SAT) has dismissed appeals filed by Top Class Capital Markets against Sebi directives that barred the stock broker from the securities market and directed it to disgorge Rs 3.78 crore in the case of alleged insider trading in Aurobindo Pharma Ltd. Dismissing the appeals, SAT, in its order on Tuesday, said "the appellant (Top Class Capital Markets) has traded and purchased the shares of Aurobindo Pharma when in possession of UPSI (Unpublished Price Sensitive Information)".

Recommended Articles

View All

The appeals were filed against two orders passed by Sebi, whereby it had imposed a penalty of Rs 7.5 crore on Top Class Capital in September 2019 and through another order in August 2020, the regulator restrained the entity from the securities market for one year and for three years in dealing with the shares of Aurobindo Pharma Ltd. In addition, Sebi had directed the broker to disgorge an amount of Rs 3.78 crore as a notional profit with interest at the rate of 12 percent per annum.
Pursuant to the orders passed by Sebi, Top Class Capital moved to SAT. Sebi, in its order, had found that Top Class Capital traded and purchased the shares of Aurobindo Pharma during July 22, 2008 to March 3, 2009, when in possession of UPSI related to certain licensing and supply agreements entered between Pfizer and Aurobindo Pharma. In the process, Top Class Capital made a notional profit of Rs 3.78 crore.
The order followed an investigation carried out by the Securities and Exchange Board of India (Sebi) into the trading of the scrip of Aurbindo Pharma during the period from July 2008 to March 2009. In the same matter, Aurobindo Pharma, its promoter P V Ramprasad Reddy, his wife P Suneela Rani, and three other entities settled the case with the markets regulator after paying over Rs 22 crore towards settlement charges.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Most Read

Market Movers

View All
Top GainersTop Losers
CurrencyCommodities
CompanyPriceChng%Chng